DCDavide Cavaliere

Davide Cavaliere

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Davide Cavaliere has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current Status of the Self-Expandable Metal Stent as a Bridge to Surgery Versus Emergency Surgery in Colorectal Cancer: Results from an Updated Systematic Review and Meta-Analysis of the Literature

    by Roberto Cirocchi, Alberto Arezzo, Paolo Sapienza, Daniele Crocetti, Davide Cavaliere, Leonardo Solaini, Giorgio Ercolani, Antonio V. Sterpetti, Andrea Mingoli, Enrico Fiori

    Background: The current use of endoscopic stenting as a bridge to surgery is not always accepted in standard clinical practice to treat neoplastic colonic obstructions. Objectives: The role of colonic self-expandable metal stent (SEMS) positioning as a bridge to resective surgery versus emergency surgery (ES) for malignant obstruction, using all new data and available variables, was studied and we focused on short- and long-term results. Materials and Methods: A systematic review with meta-analysis was performed. PubMed, SCOPUS and Web of Science databases were included. The search comprised only randomized controlled trials (RCTs) investigating the interventions that included SEMS positioning versus ES. The primary outcomes were the rates of overall postoperative mortality, clinical and technical success. The secondary outcomes were the short- and long-term results. Results: A total of 12 studies were eligible for further analyses. A laparoscopic colectomy was the most common operation performed in the SEMS group, whereas the traditional open approach was commonly used in the ES group. Intraoperative colonic lavage was seldomly performed during ES. There were no differences in mortality rates between the two groups (RR 1.06, 95% CI 0.55 to 2.04; I2 = 0%). In the SEMS group, the rate of successful primary anastomosis was significantly higher in of SEMS (69.75%) than in the ES (55.07%) (RR 1.26, 95% 245 CI 1.01 to 1.57; I2 = 86%). Conversely, the upfront Hartmann procedure was performed more frequently in the ES (39.1%) as compared to the SEMS group (23.4%) (RR 0.61, 95% CI 0.45 to 0.85; I2 = 23%). The overall postoperative complications rate was significantly lower in the SEMS group (32.74%) than in the ES group (48.25%) (RR 0.61, 95% CI 0.41 to 0.91; I2 = 65%). Conclusions: In the presence of malignant colorectal obstruction, SEMS is safe and associated with the same mortality and significantly lower morbidity than the ES group. The rate of successful primary anastomosis was significantly higher than the ES group. Nevertheless, recurrence and survival outcomes are not significantly different between the two groups. The analysis of short- and long-term results can suggest the use of SEMS as a bridge to resective surgery when it is performed by an endoscopist with adequate expertise in both colonoscopy and fluoroscopic techniques and who performed commonly colonic stenting.


  • Establishment of a “near patient model” of dedifferentiated liposarcoma: A proof of concept of the usefulness of zebrafish model.

    by Chiara Liverani, Laura Mercatali, Federico La Manna, Arwin Gronewoud, Gabri Van der Pluijm, Ewa Snaar-Jagalska, Federica Pieri, Davide Cavaliere, Alessandro De Vita, Chiara Spadazzi, et al.

    E23190 Background: Patient-derived specimens are an invaluable resource to study cancer in particular in rare tumors as Soft Tissue Sarcomas, for which several subtypes exist, that are not all covered by the matched cancer cell lines. Here we present data obtained on a primary culture of a dedifferentiated liposarcoma treated with chemotherapy and injected into the zebrafish model as the proof of concept of the usefulness of near patients models in the study of cancer cells aggressiveness and responsiveness to drugs. Methods: Primary dedifferentiated liposarcoma cells isolated from patient undergoing surgery were cultured on 3D collagen scaffolds as well as on 2D conventional supports. Cells were treated with trabectedin and with the standard combination ifosfamide and epirubicin. Aggressiveness markers were assayed by qPCR. Cells were injected in the heart cavity of zebrafish embryos, monitoring the embryos daily. Results: The 3D tumor model were enriched for cancer cells, as demonstrated by a higher percentage of MDM2-positive primary dedifferentiated liposarcoma cells respect to 2D cultures (55% vs 5%) and preserve liposarcoma-associated markers as β-catenin, MMPs and ALDH1.Chemotherapy proved effective on 3D-enriched liposarcoma cells with percentages of survival significantly lower to controls, and not significantly different between epirubicin plus ifosfamide and trabectedin alone, being respectively 48% and 53%. Liposarcoma cells injected in zebrafish were capable of surviving in the heart cavity and in later stages were scattered throughout the implantation area showing local migratory and invasive abilities, and the successful engraftment of this patient-derived liposarcoma culture in this animal model. Conclusions: The implementation of synergistic in vitro and in vivo models has allowed us to observe the aggressiveness abilities of a liposarcoma primary culture. We demonstrated in vitro a similar efficacy of trabectidin respect to the conventional first line therapy epirubicin plus ifosfamide opening new horizons to better investigate the mechanism of action of these drugs and the treatment strategy of dedifferentiated liposarcomas.

  • Open Access

    Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report

    by Alberto Bongiovanni, Nada Riva, Marianna Ricci, Laura Mercatali, Chiara Liverani, Federico La Manna, Alessandro De Vita, Davide Cavaliere, Federica Pieri, Devil Oboldi, et al.

    Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. The prognosis for this tumor is poor, with survival rates among the lowest of all soft tissue sarcomas. Surgery is the best approach for localized disease. The principal role of chemotherapy is prevalently in the treatment of metastatic disease. Trabectedin, a promising new DNA-damaging agent with a mechanism of action that differs from that of traditional alkylating agents, has been approved in Europe for the treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, We report the case of a 53-year-old woman with metastatic well differentiated uterine leiomyosarcoma refractory to multiple treatments who underwent 22 cycles of trabectedin over 30 months, obtaining a partial response according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria, with good tolerability, and maintaining the response for 10 months after trebectedin withdrawal. This very prolonged response, which persisted after drug discontinuation, suggests that trabectedin exerts an oncostatic effect rather than the cytotoxic one produced by other chemotherapeutic agents. Our experience also raises the question of the best way to evaluate trabectedin efficacy.


    • 16 May 2007
      • Vol. 59  (2) , 217-23

    [Preliminary experience with hyperthermic intraperitoneal chemo-perfusion with oxaliplatin for the treatment of peritoneal carcinomatosis due to colorectal carcinoma].

    by Gianni Mura, Massimo Framarini, Alessio Vagliasindi, Davide Cavaliere, Francesca Tauceri, Gabriele Solfrini, Carlo Milandria, Giorgio Maria Verdecchia

    Peritoneal carcinomatosis is the first cause of death after surgery for abdominal cancer, with a mean survival of 7 months. In selected patients, aggressive cytoreductive therapy combined with hyperthermic intraperitoneal chemotherapy my improve medium to long-term survival. Over the period from 2004 to January 2006, 86 patients were operated on for peritoneal carcinomatosis at the Division of Surgical Oncology, Forli, Italy. Thirteen of them were submitted to hyperthermic chemotherapy. The authors present their preliminary experience with the treatment of colorectal carcinosis by 30-min hyperthermic (41.5-42 degrees C intraperitoneal perfusion with oxaliplatin (400 mg/sq.m.) and intravenous 5-FU (400 mg/sq.m.) after complete cytoreductive surgery. The average surgical time was 606 min (range: 380-765). No intraoperative complications occurred, but 4 cases of major postoperative morbidity were reported, one of which requiring surgery. One patient died 5 months postoperatively due to lung metastases. The remaining patients are alive and free from peritoneal disease.